PATENTS

Picture

Treatment of Wounds

Application number: 20050148585







Patents by Inventor Dr Dinah Parums (US and Europe): 
 
I. US Patents:
 
This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). 
Available from: https://patents.justia.com/inventor/dinah-parums
&
https://www.paperdigest.org/expert/?name=dinah_parums
 
1. Treatment of Wounds
Publication number: 20050148585
Abstract: This invention relates to the use of cyclic guanosine 3', 5'-monophosphate type five (cGMP PDE5) inhibitors (from now on PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin, including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.
Type: Application
Filed: August 26, 2004
Publication date: July 7, 2005
Inventors: Michael Davies, Jonathan Huggins, Dinah Parums
Available from: https://patents.justia.com/inventor/dinah-parums
 
2. 12 Amino Acid Sequence
Publication number: 20050106638
Abstract: The invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Application
Filed: August 30, 2004
Publication date: May 19, 2005
Applicant: Pfizer Inc.
Inventors: Dinah Parums, Stephen Phillips, John Ridden
Available from: https://patents.justia.com/inventor/dinah-parums
& https://europepmc.org/article/PAT/US2005106638
 
3.  Target
Patent number: 6794192
Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Grant
Filed: June 28, 2001
Date of Patent: September 21, 2004
Assignee: Pfizer Inc.
Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
Available from: https://patents.justia.com/inventor/dinah-parums
 
4.  Target
Publication number: 20030040041
Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Application
Filed: June 28, 2001
Publication date: February 27, 2003
Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
Available from: https://patents.justia.com/inventor/dinah-parums
 
5.  Treatment of Wounds
Publication number: 20020065286
Abstract: This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.
Type: Application
Filed: August 10, 2001
Publication date: May 30, 2002
Inventors: Michael John Davies, Jonathan Paul Huggins, Dinah Parums
Available from: https://patents.justia.com/inventor/dinah-parums
& https://patentimages.storage.googleapis.com/bd/94/9d/b50fc52e4c9425/US20020065286A1.pdf
 
II. European Patents:
 
6. Phosphodiesterase
Priority number: GB20000016009
Application number: EP20010305392 
Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Application
Filed:  21 Jun 2001
Publication date: 21 Jun 2001
Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
Available from: http://europepmc.org/article/PAT/EP1178115#